Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.
Location: United Kingdom, England, Sheffield
Employees: 1-10
Total raised: $15.76M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | UCB Ventur... | ucbventure... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.04.2021 | - | $13.9M | - |
| 20.05.2019 | Seed | $1.85M | - |
Mentions in press and media 7
| Date | Title | Description |
| 01.07.2025 | UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss Rincell-1 addresses a multi $Bn global market opportunity whe... | Sheffield, UK, July 1 2025 – Rinri Therapeutics, a world leading company focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, is pleased to announce the approval of its Clinical Trial Application (CTA) f... |
| 22.04.2021 | Rinri Therapeutics Raises £10M in Funding | Rinri Therapeutics, a Sheffield, England, UK-based biotechnology company developing a novel stem cell therapy to restore hearing, raised a total of £10m in funding. Backers included existing investors Boehringer Ingelheim Venture Fund (BIVF... |
| 22.05.2019 | UK-based biotech startup wants to treat hearing loss with this next-gen tech | Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, announced today that it successfully secured €1.6 million in seed funding. The financing, which was co-led by Boehringer Ingelheim Venture... |
| 21.05.2019 | Term Sheet — Tuesday, May 21 | DEBUT DEAL Mary Meeker has made her first investment out of Bond Capital, the new firm she launched after spinning out of Kleiner Perkins last year. Paid Content You can't secure what you can't see From ExtraHop The funding announcement mad... |
| 20.05.2019 | Rinri Therapeutics raises €1.6 million seed to reverse hearing loss through stem cell technology | Neuropathic sensorineural hearing loss (SNHL) is estimated to affect 64 million patients in the US, and 34 million in Europe, and there are currently no pharmacological treatments available for the condition. A spin-out of Sheffield Univers... |
| 20.05.2019 | Rinri Therapeutics Raises £1.4M in Seed Funding | Rinri Therapeutics, a Sheffield, England, UK-based biotechnology company developing a novel cell-based therapy to restore hearing, secured £1.4m in seed funding. The round was co-led by Boehringer Ingelheim Venture Fund and UCB Ventures and... |
| - | Rinri Therapeutics secures £1.4 million seed funding to advance its novel regenerative cell therapy to treat sensorineural hearing loss | 20 May 2019. Rinri Therapeutics, a biotechnology company developing a novel cell- based therapy to restore hearing, announced today that it successfully secured £1.4 million in seed funding. The financing, which was co-led by Boehringer Ing... |